

				m-AMS		AZQ		Cycloctyindine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		23558	43	0.2	6	0.0	5	0.0	3	0.0	588	2.5	5646	24.3	3	0.0	9	0.0	135	0.6
	Age at baseline	<18	5290	7	0.1	2	0.0	3	0.1	1	0.0	125	2.4	1613	30.8	1	0.0	3	0.1	67	1.3
		18-19	1964	6	0.3	.	.	1	0.1	.	.	47	2.4	613	31.7	.	.	2	0.1	11	0.6
		20-24	5470	10	0.2	3	0.1	1	0.0	1	0.0	108	2.0	1427	26.4	.	.	2	0.0	25	0.5
		25-29	5110	7	0.1	1	0.0	.	.	1	0.0	164	3.2	1124	22.2	1	0.0	1	0.0	17	0.3
		30-34	3523	7	0.2	92	2.6	600	17.3	.	.	1	0.0	11	0.3
		35+	2201	6	0.3	52	2.4	269	12.4	1	0.0	.	.	4	0.2
	Years since diagnosis	5-9	2383	6	0.3	2	0.1	.	.	1	0.0	83	3.5	615	26.2	.	.	5	0.2	17	0.7
		10-14	7680	17	0.2	3	0.0	4	0.1	1	0.0	195	2.6	2058	27.1	1	0.0	4	0.1	61	0.8
		15-19	7552	11	0.1	1	0.0	1	0.0	.	.	140	1.9	1795	24.1	1	0.0	.	.	46	0.6
		20+	5943	9	0.2	1	0.0	170	2.9	1178	20.1	1	0.0	.	.	11	0.2
	Age at diagnosis	<1	1778	6	0.3	1	0.1	1	0.1	.	.	28	1.6	134	7.6	1	0.1	.	.	15	0.8
		1-4	7584	10	0.1	.	.	4	0.1	1	0.0	151	2.0	2627	35.1	1	0.0	2	0.0	67	0.9
		5-9	5282	7	0.1	4	0.1	.	.	1	0.0	163	3.1	1416	27.1	.	.	1	0.0	23	0.4
		10-14	4993	8	0.2	1	0.0	.	.	1	0.0	166	3.4	999	20.2	.	.	4	0.1	13	0.3
		15-20	3921	12	0.3	80	2.1	470	12.2	1	0.0	2	0.1	17	0.4
Males	All cases		12463	18	0.1	3	0.0	3	0.0	2	0.0	343	2.8	2976	24.2	1	0.0	4	0.0	76	0.6
	Age at baseline	<18	2841	2	0.1	2	0.1	1	0.0	.	.	74	2.6	836	29.8	.	.	1	0.0	43	1.5
		18-19	1014	3	0.3	.	.	1	0.1	.	.	30	3.0	323	32.2	.	.	1	0.1	8	0.8
		20-24	2840	6	0.2	1	0.0	1	0.0	1	0.0	53	1.9	708	25.2	.	.	1	0.0	11	0.4
		25-29	2800	3	0.1	1	0.0	111	4.0	622	22.5	.	.	1	0.0	5	0.2
		30-34	1856	2	0.1	48	2.6	321	17.5	7	0.4
		35+	1112	2	0.2	27	2.5	166	15.2	1	0.1	.	.	2	0.2
	Years since diagnosis	5-9	1326	4	0.3	1	0.1	.	.	1	0.1	52	4.0	329	25.3	.	.	3	0.2	9	0.7
		10-14	4084	6	0.1	2	0.0	2	0.0	.	.	118	2.9	1098	27.2	.	.	1	0.0	36	0.9
		15-19	3918	5	0.1	.	.	1	0.0	.	.	78	2.0	911	23.6	1	0.0	.	.	26	0.7
		20+	3135	3	0.1	1	0.0	95	3.1	638	20.6	5	0.2
	Age at diagnosis	<1	901	2	0.2	1	0.1	1	0.1	.	.	12	1.3	65	7.3	11	1.2
		1-4	3934	4	0.1	.	.	2	0.1	.	.	89	2.3	1336	34.4	37	0.9
		5-9	2955	3	0.1	2	0.1	.	.	1	0.0	100	3.4	763	26.2	.	.	1	0.0	15	0.5
		10-14	2603	5	0.2	1	0.0	98	3.8	525	20.4	.	.	2	0.1	5	0.2
		15-20	2070	4	0.2	44	2.2	287	14.1	1	0.0	1	0.0	8	0.4
Females	All cases		11095	25	0.2	3	0.0	2	0.0	1	0.0	245	2.2	2670	24.3	2	0.0	5	0.0	59	0.5
	Age at baseline	<18	2449	5	0.2	.	.	2	0.1	1	0.0	51	2.1	777	32.0	1	0.0	2	0.1	24	1.0
		18-19	950	3	0.3	17	1.8	290	31.1	.	.	1	0.1	3	0.3
		20-24	2630	4	0.2	2	0.1	55	2.1	719	27.6	.	.	1	0.0	14	0.5
		25-29	2310	4	0.2	1	0.0	53	2.3	502	21.9	1	0.0	.	.	12	0.5
		30-34	1667	5	0.3	44	2.7	279	17.0	.	.	1	0.1	4	0.2
		35+	1089	4	0.4	25	2.3	103	9.6	2	0.2
	Years since diagnosis	5-9	1057	2	0.2	1	0.1	31	3.0	286	27.4	.	.	2	0.2	8	0.8
		10-14	3596	11	0.3	1	0.0	2	0.1	1	0.0	77	2.2	960	26.9	1	0.0	3	0.1	25	0.7
		15-19	3634	6	0.2	1	0.0	62	1.7	884	24.6	20	0.6
		20+	2808	6	0.2	75	2.7	540	19.5	1	0.0	.	.	6	0.2

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
	Age at diagnosis	<1	877	4	0.5	16	1.8	69	7.9	1	0.1	.	.	4	0.5
		1-4	3650	6	0.2	.	.	2	0.1	1	0.0	62	1.7	1291	35.8	1	0.0	2	0.1	30	0.8
		5-9	2327	4	0.2	2	0.1	63	2.7	653	28.3	8	0.3
		10-14	2390	3	0.1	1	0.0	68	2.9	474	20.0	.	.	2	0.1	8	0.3
		15-20	1851	8	0.4	36	2.0	183	10.1	.	.	1	0.1	9	0.5

			m-AMSA			AZQ		Cycloctyndine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		7245	42	0.6	.	.	3	0.0	3	0.0	200	2.8	5060	71.2	3	0.0	9	0.1	43	0.6
	Age at baseline	<18	2096	7	0.3	.	.	2	0.1	1	0.0	39	1.9	1546	75.3	1	0.0	3	0.1	6	0.3
		18-19	769	6	0.8	.	.	1	0.1	.	.	15	2.0	566	75.3	.	.	2	0.3	4	0.5
		20-24	1788	10	0.6	1	0.1	35	2.0	1306	74.2	.	.	2	0.1	7	0.4
		25-29	1459	7	0.5	1	0.1	63	4.4	962	66.8	1	0.1	1	0.1	13	0.9
		30-34	761	7	0.9	25	3.4	459	62.3	.	.	1	0.1	10	1.3
		35+	372	5	1.4	23	6.3	221	60.5	1	0.3	.	.	3	0.8
	Years since diagnosis	5-9	904	6	0.7	1	0.1	28	3.1	571	64.6	.	.	5	0.6	1	0.1
		10-14	2445	17	0.7	.	.	3	0.1	1	0.0	74	3.1	1872	78.1	1	0.0	4	0.2	19	0.8
		15-19	2236	10	0.5	44	2.0	1574	71.7	1	0.0	.	.	19	0.9
		20+	1660	9	0.5	1	0.1	54	3.3	1043	63.9	1	0.1	.	.	4	0.2
	Age at diagnosis	<1	232	6	2.6	5	2.2	131	58.0	1	0.4	.	.	3	1.3
		1-4	3421	10	0.3	.	.	3	0.1	1	0.0	55	1.6	2510	74.7	1	0.0	2	0.1	11	0.3
		5-9	1754	7	0.4	1	0.1	41	2.4	1246	72.4	.	.	1	0.1	4	0.2
		10-14	1203	8	0.7	1	0.1	63	5.3	810	68.2	.	.	4	0.3	11	0.9
		15-20	635	11	1.8	36	5.8	363	59.0	1	0.2	2	0.3	14	2.2
Males	All cases		3827	18	0.5	.	.	1	0.0	2	0.1	109	2.9	2605	69.5	1	0.0	4	0.1	20	0.5
	Age at baseline	<18	1136	2	0.2	22	1.9	789	71.3	.	.	1	0.1	2	0.2
		18-19	411	3	0.7	.	.	1	0.2	.	.	8	2.0	292	71.9	.	.	1	0.2	2	0.5
		20-24	891	6	0.7	1	0.1	13	1.5	632	72.0	.	.	1	0.1	4	0.5
		25-29	783	3	0.4	1	0.1	43	5.5	518	67.4	.	.	1	0.1	3	0.4
		30-34	397	2	0.5	13	3.4	236	61.6	7	1.8
		35+	209	2	1.0	10	4.8	138	67.0	1	0.5	.	.	2	1.0
	Years since diagnosis	5-9	510	4	0.8	1	0.2	15	3.0	291	58.4	.	.	3	0.6	1	0.2
		10-14	1301	6	0.5	.	.	1	0.1	.	.	44	3.4	978	77.0	.	.	1	0.1	8	0.6
		15-19	1136	5	0.4	22	2.0	778	69.8	1	0.1	.	.	9	0.8
		20+	880	3	0.3	1	0.1	28	3.2	558	64.4	2	0.2
	Age at diagnosis	<1	110	2	1.9	2	1.9	65	61.9	1	0.9
		1-4	1809	4	0.2	.	.	1	0.1	.	.	31	1.7	1262	70.9	5	0.3
		5-9	935	3	0.3	1	0.1	24	2.6	650	71.2	.	.	1	0.1	2	0.2
		10-14	588	5	0.9	1	0.2	30	5.2	402	69.6	.	.	2	0.3	4	0.7
		15-20	385	4	1.1	22	5.8	226	60.6	1	0.3	1	0.3	8	2.1
Females	All cases		3418	24	0.7	.	.	2	0.1	1	0.0	91	2.7	2455	73.1	2	0.1	5	0.1	23	0.7
	Age at baseline	<18	960	5	0.5	.	.	2	0.2	1	0.1	17	1.8	757	80.0	1	0.1	2	0.2	4	0.4
		18-19	358	3	0.8	7	2.0	274	79.2	.	.	1	0.3	2	0.6
		20-24	897	4	0.4	22	2.5	674	76.4	.	.	1	0.1	3	0.3
		25-29	676	4	0.6	20	3.0	444	66.1	1	0.1	.	.	10	1.5
		30-34	364	5	1.4	12	3.4	223	63.0	.	.	1	0.3	3	0.8
		35+	163	3	1.9	13	8.1	83	52.2	1	0.6
	Years since diagnosis	5-9	394	2	0.5	13	3.3	280	72.5	.	.	2	0.5	.	.
		10-14	1144	11	1.0	.	.	2	0.2	1	0.1	30	2.6	894	79.3	1	0.1	3	0.3	11	1.0
		15-19	1100	5	0.5	22	2.0	796	73.7	10	0.9
		20+	780	6	0.8	26	3.4	485	63.3	1	0.1	.	.	2	0.3
	Age at diagnosis	<1	122	4	3.3	3	2.5	66	54.5	1	0.8	.	.	2	1.6
		1-4	1612	6	0.4	.	.	2	0.1	1	0.1	24	1.5	1248	79.0	1	0.1	2	0.1	6	0.4
		5-9	819	4	0.5	17	2.1	596	73.8	2	0.2

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cycloctyndine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	615	3	0.5	33	5.4	408	67.0	.	.	2	0.3	7	1.1
		15-20	250	7	2.9	14	5.8	137	56.6	.	.	1	0.4	6	2.4

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

			m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		6067	3	0.0	.	.	2	0.0	2	0.0	99	1.6	4777	80.3	2	0.0
	Age at baseline	<18	1812	1	0.1	.	.	1	0.1	1	0.1	25	1.4	1454	82.1
		18-19	666	1	0.2	.	.	9	1.4	538	82.8
		20-24	1524	15	1.0	1235	82.4
		25-29	1207	1	0.1	1	0.1	37	3.1	915	76.6	1	0.1
		30-34	590	1	0.2	6	1.0	429	75.0
		35+	268	7	2.6	206	78.6	1	0.4
	Years since diagnosis	5-9	777	16	2.1	535	70.4
		10-14	2049	3	0.1	.	.	2	0.1	1	0.0	40	2.0	1765	87.9
		15-19	1847	14	0.8	1501	82.9	1	0.1
		20+	1394	1	0.1	29	2.1	976	71.2	1	0.1
	Age at diagnosis	<1	127	3	2.4	101	81.5
		1-4	3030	1	0.0	.	.	2	0.1	1	0.0	31	1.0	2394	80.6	1	0.0
		5-9	1537	1	0.1	29	1.9	1185	78.6
		10-14	940	26	2.8	761	81.7
		15-20	433	2	0.5	10	2.4	336	80.8	1	0.2
Males	All cases		3231	1	0.0	1	0.0	65	2.0	2454	77.5	1	0.0
	Age at baseline	<18	982	17	1.7	739	77.3
		18-19	359	1	0.3	.	.	6	1.7	275	77.7
		20-24	759	5	0.7	597	79.8
		25-29	660	1	0.2	28	4.3	492	75.6
		30-34	313	5	1.6	221	72.9
		35+	158	4	2.5	130	83.3	1	0.6
	Years since diagnosis	5-9	440	11	2.5	274	63.7
		10-14	1099	1	0.1	.	.	26	2.4	917	85.5
		15-19	949	10	1.1	740	79.4	1	0.1
		20+	743	1	0.1	18	2.4	523	71.4
	Age at diagnosis	<1	63	1	1.6	50	82.0
		1-4	1591	1	0.1	.	.	19	1.2	1195	76.5
		5-9	829	1	0.1	21	2.6	624	76.9
		10-14	476	16	3.4	377	79.9
		15-20	272	8	3.0	208	79.4	1	0.4
Females	All cases		2836	3	0.1	.	.	1	0.0	1	0.0	34	1.2	2323	83.5	1	0.0
	Age at baseline	<18	830	1	0.1	.	.	1	0.1	1	0.1	8	1.0	715	87.6
		18-19	307	3	1.0	263	88.9
		20-24	765	10	1.3	638	85.0
		25-29	547	1	0.2	9	1.7	423	77.9	1	0.2
		30-34	277	1	0.4	1	0.4	208	77.3
		35+	110	3	2.8	76	71.7
	Years since diagnosis	5-9	337	5	1.5	261	79.1
		10-14	950	3	0.3	.	.	1	0.1	1	0.1	14	1.5	848	90.8
		15-19	898	4	0.4	761	86.6
		20+	651	11	1.7	453	71.0	1	0.2
	Age at diagnosis	<1	64	2	3.1	51	81.0
		1-4	1439	1	0.1	.	.	1	0.1	1	0.1	12	0.8	1199	85.2	1	0.1
		5-9	708	8	1.1	561	80.5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	464	10	2.2	384	83.5
		15-20	161	2	1.3	2	1.3	128	83.1

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		871	39	4.5	.	.	1	0.1	1	0.1	18	2.1	204	23.7	38	4.4
	Age at baseline	<18	225	6	2.7	.	.	1	0.4	.	.	4	1.8	76	34.1	4	1.8
		18-19	82	6	7.4	1	1.2	22	27.2	4	4.9
		20-24	191	10	5.3	1	0.5	5	2.6	45	23.9	6	3.2
		25-29	186	6	3.2	3	1.6	34	18.4	12	6.5
		30-34	118	6	5.2	3	2.6	19	16.7	10	8.6
		35+	69	5	7.4	2	2.9	8	11.8	2	2.9
	Years since diagnosis	5-9	81	6	7.6	1	1.3	.	.	28	35.9	1	1.3
		10-14	307	14	4.6	.	.	1	0.3	.	.	6	2.0	85	28.0	16	5.3
		15-19	301	10	3.3	4	1.3	50	16.7	18	6.0
		20+	182	9	5.0	8	4.5	41	23.0	3	1.7
	Age at diagnosis	<1	90	6	6.7	1	1.1	28	31.5	1	1.1
		1-4	299	9	3.0	.	.	1	0.3	.	.	10	3.4	82	27.5	10	3.4
		5-9	163	7	4.3	43	26.9	4	2.5
		10-14	182	8	4.5	1	0.6	3	1.7	34	19.2	10	5.6
		15-20	137	9	6.6	4	2.9	17	12.6	13	9.5
Males	All cases		427	18	4.3	1	0.2	11	2.6	98	23.4	18	4.3
	Age at baseline	<18	122	2	1.7	3	2.5	41	34.2	2	1.7
		18-19	42	3	7.1	1	2.4	14	33.3	2	4.8
		20-24	92	6	6.6	1	1.1	3	3.3	16	17.8	3	3.3
		25-29	82	3	3.7	2	2.5	17	21.0	3	3.7
		30-34	56	2	3.6	2	3.6	8	15.1	7	12.7
		35+	33	2	6.3	2	6.3	1	3.1
	Years since diagnosis	5-9	47	4	8.7	1	2.1	.	.	12	26.7	1	2.1
		10-14	152	6	4.0	5	3.3	47	31.5	8	5.4
		15-19	141	5	3.5	3	2.1	23	16.4	8	5.7
		20+	87	3	3.5	3	3.5	16	19.0	1	1.2
	Age at diagnosis	<1	39	2	5.3	1	2.6	15	39.5	1	2.6
		1-4	165	4	2.4	7	4.2	44	26.7	4	2.4
		5-9	75	3	4.1	15	20.8	2	2.7
		10-14	74	5	6.9	1	1.4	1	1.4	14	19.7	4	5.6
		15-20	74	4	5.5	2	2.7	10	13.9	7	9.5
Females	All cases		444	21	4.8	.	.	1	0.2	.	.	7	1.6	106	24.0	20	4.5
	Age at baseline	<18	103	4	3.9	.	.	1	1.0	.	.	1	1.0	35	34.0	2	2.0
		18-19	40	3	7.7	8	20.5	2	5.1
		20-24	99	4	4.1	2	2.0	29	29.6	3	3.1
		25-29	104	3	2.9	1	1.0	17	16.3	9	8.7
		30-34	62	4	6.6	1	1.6	11	18.0	3	4.9
		35+	36	3	8.3	2	5.6	6	16.7	1	2.8
	Years since diagnosis	5-9	34	2	6.1	16	48.5
		10-14	155	8	5.2	.	.	1	0.6	.	.	1	0.6	38	24.5	8	5.2
		15-19	160	5	3.1	1	0.6	27	17.0	10	6.3
		20+	95	6	6.4	5	5.3	25	26.6	2	2.1
	Age at diagnosis	<1	51	4	7.8	13	25.5
		1-4	134	5	3.8	.	.	1	0.8	.	.	3	2.3	38	28.6	6	4.5
		5-9	88	4	4.5	28	31.8	2	2.3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	108	3	2.8	2	1.9	20	18.9	6	5.7
		15-20	63	5	7.9	2	3.2	7	11.1	6	9.5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cycloctyndine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		4184	.	.	5	0.1	163	3.9	2	0.0	5	0.1
	Age at baseline	<18	891	.	.	2	0.2	51	5.8	2	0.2
		18-19	349	11	3.2	1	0.3
		20-24	1093	.	.	2	0.2	30	2.8	2	0.2
		25-29	1021	.	.	1	0.1	42	4.2	2	0.2
		30-34	581	21	3.6
		35+	249	8	3.3
	Years since diagnosis	5-9	428	.	.	1	0.2	37	8.8
		10-14	1424	.	.	3	0.2	49	3.5	1	0.1	3	0.2
		15-19	1325	.	.	1	0.1	19	1.5	1	0.1	2	0.2
		20+	1007	58	5.8
	Age at diagnosis	<1	205	.	.	1	0.5	12	5.9	2	1.0
		1-4	1223	49	4.1	1	0.1	1	0.1
		5-9	1326	.	.	4	0.3	58	4.4	1	0.1	1	0.1
		10-14	996	33	3.4	1	0.1
		15-20	434	11	2.6
Males	All cases		2276	.	.	3	0.1	93	4.2	2	0.1	3	0.1
	Age at baseline	<18	494	.	.	2	0.4	35	7.2	1	0.2
		18-19	176	5	2.9	1	0.6
		20-24	584	.	.	1	0.2	14	2.4	2	0.3
		25-29	579	28	4.9	1	0.2
		30-34	309	8	2.6
		35+	134	3	2.3
	Years since diagnosis	5-9	242	.	.	1	0.4	23	9.8
		10-14	766	.	.	2	0.3	31	4.1	1	0.1	2	0.3
		15-19	720	9	1.3	1	0.1	1	0.1
		20+	548	30	5.5
	Age at diagnosis	<1	121	.	.	1	0.8	8	6.7	2	1.7
		1-4	647	27	4.2	1	0.2
		5-9	738	.	.	2	0.3	35	4.8	1	0.1
		10-14	526	17	3.3	1	0.2
		15-20	244	6	2.6
Females	All cases		1908	.	.	2	0.1	70	3.7	2	0.1
	Age at baseline	<18	397	16	4.0	1	0.3
		18-19	173	6	3.6
		20-24	509	.	.	1	0.2	16	3.2
		25-29	442	.	.	1	0.2	14	3.2	1	0.2
		30-34	272	13	4.8
		35+	115	5	4.3
	Years since diagnosis	5-9	186	14	7.6
		10-14	658	.	.	1	0.2	18	2.8	1	0.2
		15-19	605	.	.	1	0.2	10	1.7	1	0.2
		20+	459	28	6.1
	Age at diagnosis	<1	84	4	4.8
		1-4	576	22	3.9	1	0.2
		5-9	588	.	.	2	0.3	23	3.9	1	0.2

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	470	16	3.4
		15-20	190	5	2.7

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

			m-AMSA				AZQ		Cycloctyindine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	
Both sexes	All cases	2509	.	.	4	0.2	59	2.4	1	0.0	3	0.1		
	Age at baseline	<18	493	.	.	2	0.4	17	3.5		
		18-19	202	3	1.5	1	0.5		
		20-24	662	.	.	2	0.3	10	1.5	1	0.2		
		25-29	629	19	3.1	2	0.3		
		30-34	357	9	2.5		
		35+	166	1	0.6		
	Years since diagnosis	5-9	219	.	.	1	0.5	11	5.1		
		10-14	838	.	.	3	0.4	24	2.9	1	0.1	.	.	.	1	0.1		
		15-19	778	5	0.7	2	0.3		
		20+	674	19	2.8		
	Age at diagnosis	<1	144	.	.	1	0.7	7	4.9	1	0.7		
		1-4	741	9	1.2		
		5-9	750	.	.	3	0.4	23	3.1	1	0.1	.	.	.	1	0.1		
		10-14	599	14	2.4	1	0.2		
		15-20	275	6	2.2		
Males	All cases	1302	.	.	3	0.2	38	2.9	1	0.1	2	0.2		
	Age at baseline	<18	258	.	.	2	0.8	15	5.9		
		18-19	102	3	3.0	1	1.0		
		20-24	325	.	.	1	0.3	5	1.5	1	0.3		
		25-29	351	12	3.4	1	0.3		
		30-34	178	3	1.7		
		35+	88		
	Years since diagnosis	5-9	117	.	.	1	0.9	8	6.8		
		10-14	437	.	.	2	0.5	19	4.4	1	0.2	.	.	.	1	0.2		
		15-19	391	3	0.8	1	0.3		
		20+	357	8	2.3		
	Age at diagnosis	<1	81	.	.	1	1.2	6	7.4	1	1.2		
		1-4	373	6	1.6		
		5-9	394	.	.	2	0.5	15	3.8	1	0.3		
		10-14	302	8	2.7	1	0.3		
		15-20	152	3	2.0		
Females	All cases	1207	.	.	1	0.1	21	1.8	1	0.1		
	Age at baseline	<18	235	2	0.9		
		18-19	100		
		20-24	337	.	.	1	0.3	5	1.5		
		25-29	278	7	2.6	1	0.4		
		30-34	179	6	3.4		
		35+	78	1	1.3		
	Years since diagnosis	5-9	102	3	3.0		
		10-14	401	.	.	1	0.3	5	1.3		
		15-19	387	2	0.5	1	0.3		
		20+	317	11	3.5		
	Age at diagnosis	<1	63	1	1.6		
		1-4	368	3	0.8		
		5-9	356	.	.	1	0.3	8	2.3	1	0.3		

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	297	6	2.0
		15-20	123	3	2.5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

			m-AMSA		AZQ		Cycloctyndine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid		
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%		
Both sexes	All cases		979	.	.	1	0.1	86	8.9	1	0.1	1	0.1
	Age at baseline	<18	233	27	11.7	1	0.4
		18-19	77	6	8.1
		20-24	273	15	5.6	1	0.4
		25-29	236	.	.	1	0.4	19	8.1
		30-34	126	12	9.6
		35+	34	7	21.9
	Years since diagnosis	5-9	119	20	17.4
		10-14	333	22	6.7	1	0.3
		15-19	323	.	.	1	0.3	12	3.8	1	0.3
		20+	204	32	15.9
	Age at diagnosis	<1	23	2	9.1	1	4.5
		1-4	279	30	10.9	1	0.4
		5-9	402	.	.	1	0.3	31	7.8
		10-14	217	19	8.9
		15-20	58	4	7.3
Males	All cases		599	50	8.5	1	0.2	1	0.2
	Age at baseline	<18	141	19	13.8	1	0.7
		18-19	43	1	2.4
		20-24	177	7	4.0	1	0.6
		25-29	145	15	10.4
		30-34	71	5	7.1
		35+	22	3	15.0
	Years since diagnosis	5-9	72	13	19.1
		10-14	196	12	6.2	1	0.5
		15-19	207	5	2.4	1	0.5
		20+	124	20	16.5
	Age at diagnosis	<1	16	2	13.3	1	6.7
		1-4	168	18	10.9	1	0.6
		5-9	257	19	7.5
		10-14	123	9	7.4
		15-20	35	2	6.3
Females	All cases		380	.	.	1	0.3	36	9.5
	Age at baseline	<18	92	8	8.7
		18-19	34	5	15.2
		20-24	96	8	8.4
		25-29	91	.	.	1	1.1	4	4.4
		30-34	55	7	12.7
		35+	12	4	33.3
	Years since diagnosis	5-9	47	7	14.9
		10-14	137	10	7.4
		15-19	116	.	.	1	0.9	7	6.1
		20+	80	12	15.0
	Age at diagnosis	<1	7

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		1-4	111	12	10.9
		5-9	145	.	.	1	0.7	12	8.3
		10-14	94	10	10.8
		15-20	23	2	8.7

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		2827	1	0.0	1	0.0	12	0.4	2	0.1
	Age at baseline	<18	55	1	1.8
		18-19	55
		20-24	328	2	0.6
		25-29	733	4	0.6
		30-34	862	3	0.4	1	0.1
		35+	794	1	0.1	1	0.1	2	0.3	1	0.1
	Years since diagnosis	5-9	221	3	1.4
		10-14	867	2	0.2	1	0.1
		15-19	930	1	0.1	4	0.4	1	0.1
		20+	809	1	0.1	3	0.4
	Age at diagnosis	1-4	71
		5-9	353
		10-14	1026	7	0.7
		15-20	1377	1	0.1	1	0.1	5	0.4	2	0.1
Males	All cases		1458	1	0.1	8	0.6
	Age at baseline	<18	42	1	2.4
		18-19	44
		20-24	207	2	1.0
		25-29	401	3	0.8
		30-34	429	2	0.5
		35+	335	1	0.3
	Years since diagnosis	5-9	126	3	2.4
		10-14	441	2	0.5
		15-19	492	2	0.4
		20+	399	1	0.3	1	0.3
	Age at diagnosis	1-4	52
		5-9	259
		10-14	522	5	1.0
		15-20	625	1	0.2	3	0.5
Females	All cases		1369	1	0.1	4	0.3	2	0.1
	Age at baseline	<18	13
		18-19	11
		20-24	121
		25-29	332	1	0.3
		30-34	433	1	0.2	1	0.2
		35+	459	1	0.2	2	0.4	1	0.2
	Years since diagnosis	5-9	95
		10-14	426	1	0.2
		15-19	438	1	0.2	2	0.5	1	0.2
		20+	410	2	0.5
	Age at diagnosis	1-4	19
		5-9	94
		10-14	504	2	0.4
		15-20	752	1	0.1	2	0.3	2	0.3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cycloctyndine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases	1915	.	.	1	0.1	209	11.0	569	30.0	
	Age at baseline	<18	200	25	12.6	65	32.7	
		18-19	119	21	17.8	47	39.8	
		20-24	405	.	.	1	0.2	.	.	.	39	9.7	116	28.9	
		25-29	526	59	11.3	157	30.4	
		30-34	438	45	10.3	138	31.7	
		35+	227	20	9.0	46	20.6	
	Years since diagnosis	5-9	132	.	.	1	0.8	.	.	.	15	11.4	40	30.5	
		10-14	609	65	10.7	182	30.1	
		15-19	657	75	11.5	215	33.1	
		20+	517	54	10.6	132	25.9	
	Age at diagnosis	<1	12	3	25.0	3	25.0	
		1-4	315	42	13.5	115	37.2	
		5-9	579	64	11.1	168	29.2	
		10-14	602	.	.	1	0.2	.	.	.	69	11.5	181	30.2	
		15-20	407	31	7.7	102	25.5	
Males	All cases	1290	135	10.5	360	28.2	
	Age at baseline	<18	138	15	10.9	45	32.8	
		18-19	87	17	19.8	31	36.0	
		20-24	264	24	9.1	72	27.4	
		25-29	367	40	11.0	101	28.0	
		30-34	286	26	9.1	83	29.1	
		35+	148	13	8.9	28	19.2	
	Years since diagnosis	5-9	99	12	12.1	34	34.7	
		10-14	413	43	10.5	117	28.5	
		15-19	426	46	10.8	130	30.7	
		20+	352	34	9.8	79	22.8	
	Age at diagnosis	<1	3	
		1-4	211	29	13.9	72	35.0	
		5-9	404	41	10.2	112	27.9	
		10-14	409	50	12.2	118	28.9	
		15-20	263	15	5.8	58	22.4	
Females	All cases	625	.	.	1	0.2	74	12.0	209	33.9	
	Age at baseline	<18	62	10	16.1	20	32.3	
		18-19	32	4	12.5	16	50.0	
		20-24	141	.	.	1	0.7	.	.	.	15	10.8	44	31.7	
		25-29	159	19	12.1	56	35.9	
		30-34	152	19	12.6	55	36.4	
		35+	79	7	9.1	18	23.4	
	Years since diagnosis	5-9	33	.	.	1	3.0	.	.	.	3	9.1	6	18.2	
		10-14	196	22	11.3	65	33.5	
		15-19	231	29	12.8	85	37.4	
		20+	165	20	12.2	53	32.5	
	Age at diagnosis	<1	9	3	33.3	3	33.3	

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		1-4	104	13	12.6	43	41.7
		5-9	175	23	13.1	56	32.2
		10-14	193	.	.	1	0.5	19	10.0	63	33.2
		15-20	144	16	11.3	44	31.2

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases	2070	
	Age at baseline	<18	761
		18-19	275
		20-24	611
		25-29	342
		30-34	66
		35+	15
	Years since diagnosis	5-9	167
		10-14	675
		15-19	679
		20+	549
	Age at diagnosis	<1	301
		1-4	1261
		5-9	434
		10-14	54
		15-20	20
Males	All cases	917	
	Age at baseline	<18	369
		18-19	111
		20-24	252
		25-29	152
		30-34	27
		35+	6
	Years since diagnosis	5-9	74
		10-14	307
		15-19	289
		20+	247
	Age at diagnosis	<1	149
		1-4	564
		5-9	177
		10-14	19
		15-20	8
Females	All cases	1153	
	Age at baseline	<18	392
		18-19	164
		20-24	359
		25-29	190
		30-34	39
		35+	9
	Years since diagnosis	5-9	93
		10-14	368
		15-19	390
		20+	302
	Age at diagnosis	<1	152
		1-4	697
		5-9	257

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	35
		15-20	12

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

			m-AMSA				AZQ		Cycloctyndine		Deoxycoformycin		Hydrea		L-Aspariginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	
Both sexes	All cases	1798	11	0.6	1	0.1	85	4.8	
	Age at baseline	<18	889	8	0.9	1	0.1	59	6.7	
		18-19	216	6	2.8	
		20-24	504	3	0.6	18	3.6	
		25-29	150	2	1.4	
		30-34	34	
		35+	5	
	Years since diagnosis	5-9	152	2	1.3	1	0.7	16	10.7	
		10-14	558	5	0.9	38	6.8	
		15-19	594	1	0.2	24	4.1	
		20+	494	3	0.6	7	1.4	
	Age at diagnosis	<1	912	8	0.9	10	1.1	
		1-4	706	3	0.4	1	0.1	55	7.9	
		5-9	137	18	13.4	
		10-14	27	1	3.8	
		15-20	16	1	6.3	
Males	All cases	870	4	0.5	1	0.1	53	6.1	
	Age at baseline	<18	440	2	0.5	1	0.2	40	9.1	
		18-19	94	5	5.3	
		20-24	255	2	0.8	7	2.8	
		25-29	65	1	1.6	
		30-34	14	
		35+	2	
	Years since diagnosis	5-9	72	2	2.8	1	1.4	8	11.3	
		10-14	274	26	9.5	
		15-19	283	16	5.7	
		20+	241	2	0.8	3	1.3	
	Age at diagnosis	<1	470	2	0.4	8	1.7	
		1-4	317	2	0.6	1	0.3	32	10.2	
		5-9	67	13	19.7	
		10-14	10	
		15-20	6	
Females	All cases	928	7	0.8	32	3.5	
	Age at baseline	<18	449	6	1.3	19	4.3	
		18-19	122	1	0.8	
		20-24	249	1	0.4	11	4.4	
		25-29	85	1	1.2	
		30-34	20	
		35+	3	
	Years since diagnosis	5-9	80	8	10.1	
		10-14	284	5	1.8	12	4.2	
		15-19	311	1	0.3	8	2.6	
		20+	253	1	0.4	4	1.6	
	Age at diagnosis	<1	442	6	1.4	2	0.5	
		1-4	389	1	0.3	23	6.0	
		5-9	70	5	7.4	

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	17	1	6.3
		15-20	10	1	10.0

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1588	2	0.1	.	.	3	0.2	1	0.1
	Age at baseline	<18	313	1	0.3	.	.	2	0.6
		18-19	115
		20-24	382	1	0.3
		25-29	351	1	0.3
		30-34	264	1	0.4
		35+	163
	Years since diagnosis	5-9	165
		10-14	473	1	0.2	.	.	2	0.4
		15-19	498	1	0.2	.	.	1	0.2	1	0.2
		20+	452
	Age at diagnosis	<1	108	1	0.9
		1-4	507	1	0.2	.	.	2	0.4
		5-9	361	1	0.3
		10-14	311	1	0.3
		15-20	301
Males	All cases		847	2	0.2	.	.	1	0.1
	Age at baseline	<18	179	1	0.6
		18-19	58
		20-24	213	1	0.5
		25-29	179
		30-34	139	1	0.7
		35+	79
	Years since diagnosis	5-9	89
		10-14	264	1	0.4
		15-19	252	1	0.4	.	.	1	0.4
		20+	242
	Age at diagnosis	<1	44	1	2.3
		1-4	293	1	0.3
		5-9	202
		10-14	167	1	0.6
		15-20	141
Females	All cases		741	2	0.3	1	0.1
	Age at baseline	<18	134	2	1.5
		18-19	57
		20-24	169
		25-29	172	1	0.6
		30-34	125
		35+	84
	Years since diagnosis	5-9	76
		10-14	209	2	1.0
		15-19	246	1	0.4
		20+	210
	Age at diagnosis	<1	64
		1-4	214	2	0.9
		5-9	159	1	0.6

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	144
		15-20	160

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1931	1	0.1	1	0.1
	Age at baseline	<18	85
		18-19	66
		20-24	359	1	0.3	1	0.3
		25-29	528
		30-34	517
		35+	376
	Years since diagnosis	5-9	214	1	0.5
		10-14	629	1	0.2
		15-19	633
		20+	455
	Age at diagnosis	<1	8
		1-4	80
		5-9	338
		10-14	774	1	0.1
		15-20	731	1	0.1
Males	All cases		978
	Age at baseline	<18	43
		18-19	33
		20-24	174
		25-29	274
		30-34	255
		35+	199
	Years since diagnosis	5-9	114
		10-14	318
		15-19	320
		20+	226
	Age at diagnosis	<1	4
		1-4	41
		5-9	173
		10-14	362
		15-20	398
Females	All cases		953	1	0.1	1	0.1
	Age at baseline	<18	42
		18-19	33
		20-24	185	1	0.5	1	0.5
		25-29	254
		30-34	262
		35+	177
	Years since diagnosis	5-9	100	1	1.0
		10-14	311	1	0.3
		15-19	313
		20+	229
	Age at diagnosis	<1	4
		1-4	39
		5-9	165

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	412	1	0.2
		15-20	333	1	0.3

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		685	1	0.1
	Age at baseline	<18	54
		18-19	33
		20-24	157	1	0.6
		25-29	193
		30-34	153
		35+	95
	Years since diagnosis	5-9	90
		10-14	231	1	0.4
		15-19	214
		20+	150
	Age at diagnosis	<1	4
		1-4	50
		5-9	170
		10-14	257	1	0.4
		15-20	204
Males	All cases		353
	Age at baseline	<18	24
		18-19	17
		20-24	78
		25-29	99
		30-34	83
		35+	52
	Years since diagnosis	5-9	48
		10-14	109
		15-19	115
		20+	81
	Age at diagnosis	<1	2
		1-4	26
		5-9	84
		10-14	135
		15-20	106
Females	All cases		332	1	0.3
	Age at baseline	<18	30
		18-19	16
		20-24	79	1	1.3
		25-29	94
		30-34	70
		35+	43
	Years since diagnosis	5-9	42
		10-14	122	1	0.8
		15-19	99
		20+	69
	Age at diagnosis	<1	2
		1-4	24
		5-9	86

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included

				m-AMSA		AZQ		Cyclocytidine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
		10-14	122	1	0.8
		15-20	98

				m-AMSA		AZQ		Cycloctyndine		Deoxycoformycin		Hydrea		L-Asparaginase		Mithramycin		Myeleran		Retinoic acid	
			All cases	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Both sexes	All cases		1149	1	0.1
	Age at baseline	<18	25
		18-19	27
		20-24	183	1	0.5
		25-29	317
		30-34	337
		35+	260
	Years since diagnosis	5-9	118	1	0.8
		10-14	361
		15-19	390
		20+	280
	Age at diagnosis	1-4	21
		5-9	151
		10-14	491
		15-20	486	1	0.2
Males	All cases		577
	Age at baseline	<18	18
		18-19	12
		20-24	86
		25-29	165
		30-34	158
		35+	138
	Years since diagnosis	5-9	64
		10-14	190
		15-19	190
		20+	133
	Age at diagnosis	1-4	11
		5-9	76
		10-14	220
		15-20	270
Females	All cases		572	1	0.2
	Age at baseline	<18	7
		18-19	15
		20-24	97	1	1.0
		25-29	152
		30-34	179
		35+	122
	Years since diagnosis	5-9	54	1	1.9
		10-14	171
		15-19	200
		20+	147
	Age at diagnosis	1-4	10
		5-9	75
		10-14	271
		15-20	216	1	0.5

CCSS data from Jan2020 data freeze-all % based on denominator with non-missing values
 Data for patients with medical records abstraction and completed baseline qx, info in 1st 5 years
 If the starting date for a drug was not clearly prior to study entry, they are not included